Eli Lilly continues to command a premium valuation as its GLP-1 engine drives 47% revenue growth, with analysts setting a $1,220 price target despite ongoing pricing headwinds.
Eli Lilly maintains a strong buy rating due to its robust 47% revenue growth and consistent EPS beats, driven primarily by the success of its Mounjaro and Zepbound franchises. The company's premium valuation is justified by its superior growth metrics compared to peers like Novo Nordisk and Merck, with significant future upside potential tied to the upcoming BLA submission for its triple-agonist, Retatrutide.
The price target is $1,220.42 over the next 12 months.
Lilly's 24x forward P/E is justified by its 47.7% quarterly revenue growth, compared to Novo Nordisk's 2.1% growth.
Novo Nordisk is mentioned as the only GLP-1 peer with slower growth, justifying Lilly's premium.
Merck serves as a diversified pharma comparison with lower growth and patent cliff concerns.
Eli Lilly (LLY) earns a buy rating and a $1,220 price target, supported by a 47% surge in quarterly revenue and consistent EPS beats. While the company faces pricing pressure, its dominant GLP-1 franchise and the upcoming 2027 BLA submission for retatrutide justify its premium valuation compared to peers like Novo Nordisk and Merck.
The primary risks include realized price declines, which hit 13% in Q2, and potential concentration risk within the incretin franchise.
Lilly trades at a forward P/E of 24, which is higher than Novo Nordisk (14) and Merck (16), but analysts argue this is justified by Lilly's superior 47.7% revenue growth.